Related Experiment Video
Updated: Jun 24, 2025
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.0K
Intravenous Odatroltide for Acute Ischemic Stroke Within 24 Hours of Onset: A Phase 2, Multicenter, Randomized,
A-Ching Chao1,2, Tsong-Hai Lee3, Luther C Pettigrew4
1Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Drug Design, Development and Therapy
|June 11, 2024
Summary
Odatroltide (LT3001) appears safe for acute ischemic stroke patients, showing potential for improved neurological and functional outcomes compared to placebo. Further clinical trials are needed to confirm these promising results.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Odatroltide (LT3001) is a novel synthetic peptide designed to address occluded blood vessels and reduce reperfusion injury.
- Previous studies in animal models demonstrated the safety and efficacy of odatroltide in embolic stroke scenarios.
Purpose of the Study:
- To evaluate the safety and tolerability of intravenous odatroltide administration in acute ischemic stroke patients.
- To assess odatroltide's impact on neurological and functional recovery within 24 hours of stroke onset.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 24 patients with acute ischemic stroke (NIHSS 4-30).
- Patients received a single intravenous dose of odatroltide (0.025 mg/kg) or placebo in a 2:1 ratio within 24 hours of symptom onset.
- The primary safety endpoint was symptomatic intracranial hemorrhage (sICH) within 36 hours; functional outcomes were assessed using the modified Rankin Scale and NIHSS at 90 and 30 days, respectively.
Main Results:
- No symptomatic intracranial hemorrhage (sICH) occurred in either the odatroltide or placebo group.
- Odatroltide treatment showed a trend towards better functional outcomes, with 21% achieving an excellent outcome (mRS 0-1) versus 14% in the placebo group.
- Major neurological improvement (NIHSS reduction ≥4) was observed in 47% of odatroltide recipients compared to 14% of placebo recipients, particularly in patients with NIHSS ≥6 (78% improvement).
Conclusions:
- Intravenous odatroltide administered within 24 hours of ischemic stroke onset appears safe and potentially beneficial for neurological and functional recovery.
- The study suggests odatroltide may improve outcomes in acute ischemic stroke patients, warranting further investigation.
- Larger, phase clinical trials are necessary to definitively establish the efficacy and safety profile of odatroltide.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
01:29Drug Delivery: Parenteral Route
494
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
494
01:14Prevention of Further Absorption of Poison
817
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
817